| Pharmaceuticals Industry | Healthcare Sector | Mr. Sichuan Liu CEO | XSHE Exchange | CNE100000PW7 ISIN |
| China Country | 21,864 Employees | - Last Dividend | 22 Jul 2015 Last Split | 3 Jun 2010 IPO Date |
Sichuan Kelun Pharmaceutical Co., Ltd. is a prominent enterprise in the pharmaceutical industry based in Chengdu, the People's Republic of China. Established in 1996, the company has carved a niche for itself through the research, development, manufacture, distribution, and sale of pharmaceutical products within China. Operating as a subsidiary of Sichuan Kelun Industry Group CO., LTD., it has demonstrated a steadfast commitment to healthcare and innovation, providing a wide range of pharmaceutical products and medical devices. The organization’s efforts to ensure the availability of high-quality healthcare products have made it a key player in the pharmaceutical sector.
These are sterile preparations designed to be administered directly into the bloodstream or body tissue. They are ideal for delivering medications or nutrients that need to be distributed quickly and efficiently throughout the body.
Includes a variety of pharmaceutical forms intended for oral administration, such as tablets, capsules, and liquids. These products cater to a wide range of therapeutic areas, providing patients with different options for their treatment.
This innovative product combines a plastic ampoule and a powder/liquid dual-chamber system for infusions, enhancing the safety, efficacy, and convenience of medication administration.
Sichuan Kelun Pharmaceutical provides a broad array of medical devices, including but not limited to infusion sets, injection syringes, detained needles, nebulizers, and blood sampling tools. These devices are vital for various medical procedures and therapies, ensuring efficiency and safety.
The company offers a range of products available for purchase without a prescription. These over-the-counter (OTC) products include medications for common conditions and symptoms, providing accessible healthcare options to the public.